Chris Morris


  • 1.48 Chemistry

Accepting PhD Students

If you made any changes in Pure these will be visible here soon.

Personal profile


PhD Positions

Click here for current PhD opportunities in PHA. But feel free to email me to discuss projects outside these areas and alternative sources of funding.

Chris graduated with an MPharm degree from Cardiff University in 2002. His PhD studies involved investigations on the endocytic traficking of macromolecules in the lung epithelium. In 2007 Chris assumed a post-doctoral position on the EPSRC-funded Nanomedicine Platform Grant (Departments of Chemistry & Pharmacy, Cardiff University) where he led a small inter-disciplinary research group looking at the design and synthesis of novel nanomedicines for enhanced pulmonary macromolecule delivery. Subsequently, Chris worked with scientists from the Defence & Science Technology Laboratory (Porton Down, UK) on a collaborative project that investigated the bioavailability of antimicrobial peptides following delivery into the intact lung. In September 2010 Chris joined UEA as a Lecturer in Drug Delivery and Pharmaceutics.

Chris’ main research interests are in the area of experimental peptide therapeutics and their activity in biological models. Current projects include:

  • Phage display isolation of melanoma targeting peptides
  • SerpinA12 activity in malignant melanoma
  • Targeting autocrine growth signals (GRP) in small cell lung cancer
  • The use of phage display to identify DNA-binding and lectin-binding ligands

Current Group Members

Mohammad Akbar (PhD Student)

Sandeep Bahia (PhD student)

Hassan Boudjelal (PhD student) 

Shannon Conway (PhD student)


Selected publications

Antimicrobial Nanoplexes meet Model Bacterial Membranes:the key role of cardiolipin

Marín-Menéndez A, Montis C, Díaz-Calvo T, Carta D, Hatzixanthis K, Morris CJ, McArthur M, Berti D

Sci. Rep. 2017; 7: 41242.  doi: 10.1038/srep41242

Selectivity in the Impact of P-Glycoprotein Upon Pulmonary Absorption of Airway-Dosed Substrates: A Study in Ex Vivo Lung Models Using Chemical Inhibition and Genetic Knockout

Al-Jayyoussi, Ghaith, Price, Daniel F, Francombe, Danielle, Taylor, Glyn, Smith, Mathew W, Morris, Chris, Edwards, Chris D, Eddershaw, Peter, Gumbleton, Mark

J. Pharm. Sci., 2013 102(9):3382-94.
DOI: 10.1002/jps.23587

Maximal extent of translocation of single-walled carbon nanotubes from lung airways of the rat
Matthews IP, Gregory CJ, Aljayyoussi G, Morris CJ, McDonald I, Hoogendoorn B, Gumbleton M
Environ Toxicol Pharmacol., 2013, 35(3):461-464.
DOI: 10.1016/j.etap.2013.02.002

Enhanced pulmonary absorption of a macromolecule through coupling to a sequence-specific phage display-derived peptide.
Morris CJ, Smith MW, Griffiths PC, McKeown NB, Gumbleton M.
Journal of Controlled Release, 2011, 151 (1). pp. 83-94.

Pegylation of antimicrobial peptide maintains the active peptide conformation, model membrane interactions and antimicrobial activity while improving lung tissue biocompatibility following airway delivery.
Antimicrobial Agents and Chemotherapy, 2012, 56 (6). pp. 3298-3308.

Spatial expression and functionality of drug transporters in the intact lung: Objectives for further research.
M. Gumbleton, G.Al-Jayyoussi, A. Crandon-Lewis, D. Francombe, K. Kreitmeyr, C.J. Morris & M. Smith.
Advanced Drug Delivery Reviews, 2010, 63 (1-2). pp. 110-118.
DOI: 10.1016/j.addr.2010.09.008

PGSE-NMR and SANS studies of the interaction of model polymer therapeutics with mucin.
P.C. Griffiths, P. Occhipinti, C.J. Morris, Heenan R, King S, Gumbleton M
Biomacromolecules. 2010, 11, 120-125
DOI: 10.1021/bm9009667


External Activities

  • Refereeing for J. Drug Target., J. Pharm. Sci., Pharm, Res,, Biosens & Bioelec, Adv, Drug Deliv, Rev., JCIS, Biochem. J., Int. J. Pharm.
  • Grant reviewer for AICR, BBSRC, EPSRC, Cancer Research Wales
  • Editorial board member for BioImpacts
  • Invited Talks:
  • Irish Drug Delivery Network Cluster Conference, , 2010. Presentation entitled “Peptide-polymer conjugates: experimental pulmonary therapeutics and enabling technologies for macromolecular drug delivery”
  • 2nd EUFEPS Conference on Monoclonal Antibodies, Crowne Plaza Hotel, Heidelberg, Germany 3-6th June 2008. Lecture entitled “Antibody transport across biological barriers”
  • Roche Symposium for Leading Scientists of the Next Decade (March 14-16 2006, Basel). “Uptake of macromolecular via vesicular mechanisms present in pulmonary epithelial cells - Exploitation to achieve effective protein and peptide delivery”

Expertise related to UN Sustainable Devlopment Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being


Recent external collaboration on country/territory level. Dive into details by clicking on the dots or